Fem-Dophilus® contains two patented and clinically documented probiotic strains, Lactobacillus rhamnosus, GR-1® and Lactobacillus reuteri, RC-14®, discovered and developed by Dr. Gregor Reid and Dr. Andrew Cruse at Urex Biotech. Over 25 years of research supports the oral use of GR-1 and RC-14 to colonize and promote healthy vaginal and urinary tract health. A special manufacturing process protects the probiotic strains in Fem-Dophilus from stomach acid and enhances probiotic bacterial survival to the lower intestine.

GR-1/RC-14 and Vaginal Flora (also called microbiota)

In one of the randomized clinical trials, 75% of women in the GR-1/RC-14 probiotic group experienced significant improvement in vaginal flora composition, while only 34% of women in the placebo (non-probiotic) group experienced similar improvement.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.